Anti-Inflammatory Effect of Amlodipine Plus Atorvastatin Treatment on Carotid Atherosclerosis in Zucker Metabolic Syndrome Rats

Translational Stroke Research

Volumn 3, Issue 4, 2012, Pages 435-441

  Zhang, Xuemei ^a   Tian, Fengfeng ^a   Kawai, Hiromi ^a   Kurata, Tomoko ^a   Deguchi, Shoko ^a   Deguchi, Kentaro ^a   Shang, Jingwei ^a   Liu, Ning ^a   Liu, Wentao ^a   Ikeda, Yoshio ^a   Matsuura, Tohru ^a   Kamiya, Tatsushi ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Amlodipine; Atorvastatin; Common carotid artery; Zucker metabolic syndrome rat

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AMLODIPINE; ATORVASTATIN; BONE MORPHOGENETIC PROTEIN 2; NOTCH1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 84869880552     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-012-0198-1     Document Type: Article

References (31)

1. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24(4): 683-9.
2. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004; 110(10): 1245-50.
3. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005; 28(2): 385-90.
4. Ionescu E, Sauter JF, Jeanrenaud B. Abnormal oral glucose tolerance in genetically obese (fa/fa) rats. Am J Physiol. 1985; 248(5 Pt 1): E500-6.
5. Vaziri ND, Xu ZG, Shahkarami A, Huang KT, Rodriguez-Iturbe B, Natarajan R. Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. Kidney Int. 2005; 68(6): 2787-93.
6. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension. 2000; 36(5): 901-6.
7. Yoshii T, Iwai M, Li Z, Chen R, Ide A, Fukunaga S, et al. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res. 2006; 29(6): 457-66.
8. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998; 138(2): 271-80.
9. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002; 359(9312): 1125-6.
10. Tsuchiya A, Nagotani S, Hayashi T, Deguchi K, Sehara Y, Yamashita T, et al. Macrophage infiltration, lectin-like oxidized-LDL receptor-1, and monocyte chemoattractant protein-1 are reduced by chronic HMG-CoA reductase inhibition. Curr Neurovasc Res. 2007; 4(4): 268-73.
11. Robinson JG. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am J Cardiol. 2008; 101(7): 1009-15.
12. Yamanaka K, Suzuki M, Munehasu S, Ishiko J. Antihypertensive effects of amlodipine, a new calcium antagonist. Nihon Yakurigaku Zasshi. 1991; 97(2): 115-26.
13. Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Nishi SP, Martinez JD, et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation. 2006; 114(9): 929-35.
14. Kawai H, Deguchi S, Deguchi K, Yamashita T, Ohta Y, Shang J et al. Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat. Brain Res. 1368: 317-23.
15. Zhang X, Deguchi K, Yamashita T, Ohta Y, Shang J, Tian F et al. Temporal and spatial differences of multiple protein expression in the ischemic penumbra after transient MCAO in rats. Brain Res. 1343: 143-52.
16. Mule G, Cottone S, Mongiovi R, Cusimano P, Mezzatesta G, Seddio G, et al. Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients. Nutr Metab Cardiovasc Dis. 2006; 16(1): 54-9.
17. Arenillas JF, Sandoval P, Perez de la Ossa N, Millan M, Guerrero C, Escudero D, et al. The metabolic syndrome is associated with a higher resistance to intravenous thrombolysis for acute ischemic stroke in women than in men. Stroke. 2009; 40(2): 344-9.
18. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340(2): 115-26.
19. Trion A, de Maat M, Jukema W, Maas A, Offerman E, Havekes L, et al. Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice. J Cardiovasc Pharmacol. 2006; 47(1): 89-95.
20. Amarenco P, Bogousslavsky J, Callahan 3rd A, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355(6): 549-59.
21. Hong H, Zeng JS, Kreulen DL, Kaufman DI, Chen AF. Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am J Physiol Heart Circ Physiol. 2006; 291(5): H2210-5.
22. Nagotani S, Hayashi T, Sato K, Zhang W, Deguchi K, Nagano I, et al. Reduction of cerebral infarction in stroke-prone spontaneously hypertensive rats by statins associated with amelioration of oxidative stress. Stroke. 2005; 36(3): 670-2.
23. Hayashi T, Hamakawa K, Nagotani S, Jin G, Li F, Deguchi K, et al. HMG CoA reductase inhibitors reduce ischemic brain injury of Wistar rats through decreasing oxidative stress on neurons. Brain Res. 2005; 1037(1-2): 52-8.
24. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res. 2005; 97(2): 105-14.
25. Albrecht D, Kaspers S, Fussl R, Hopp HW, Sechtem U. Coronary plaque morphology affects stent deployment: assessment by intracoronary ultrasound. Cathet Cardiovasc Diagn. 1996; 38(3): 229-35.
26. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int. 2001; 60(2): 472-9.
27. Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation. 2005; 111(18): 2364-72.
28. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004; 24(7): 1161-70.
29. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993; 91(4): 1800-9.
30. Schluesener HJ, Meyermann R. Immunolocalization of BMP-6, a novel TGF-beta-related cytokine, in normal and atherosclerotic smooth muscle cells. Atherosclerosis. 1995; 113(2): 153-6.
31. Iso T, Hamamori Y, Kedes L. Notch signaling in vascular development. Arterioscler Thromb Vasc Biol. 2003; 23(4): 543-53.